|
|
|
206A PRISM BioLab Co.,LTD
|
|
| 02/13/2026 16:30 |
[Summary] Non-consolidated Financial Results for the Three Months of the Fiscal Year Ending September 30, 2026 (Under Japanese GAAP) |
| 01/21/2026 16:00 |
Phase 1 clinical research results of E7386, Jointly Created by PRISM BioLab and Eisai, Published in ESMO OPEN |
| 12/17/2025 16:00 |
Nonclinical research results of E7386, Jointly Created by PRISM BioLab and Eisai, Published in Clinical Cancer Research |
| 12/17/2025 16:00 |
PRISM BioLab and Talus Bioscience Join Forces to Discover Novel Inhibitors of Transcription Factor and Protein-Protein Interaction Targets |
| 11/14/2025 16:30 |
[Summary] Financial Results for the Year |
| 11/14/2025 16:30 |
PRISM BioLab Achieved Initial Milestone and Receives the Milestone Payment in Drug Discovery Collaboration with Ono Pharmaceutical Co., Ltd. |
| 10/17/2025 18:00 |
Eisai to Present Clinical Trial and Biomarker Exploration Results of E7386, Co-Created with PRISM BioLab, at the ESMO Annual Congress |
| 10/03/2025 16:00 |
Notice Regarding the Termination of the Collaboration & License Option Agreement with Servier |
| 05/23/2025 08:59 |
Eisai to Present E7386, Co-created by PRISM BioLab and Eisai, at the ASCO(American Society of Clinical Oncology) Annual Meeting |
| 04/14/2025 16:00 |
PRISM BioLab and Elix Join Forces to Accelerate AI-Driven Drug |
|